Bei­jing CRO ex­pands agree­ment with Mer­ck KGaA; Ear­ly-stage ven­ture firm clos­es its first fund

On Thurs­day morn­ing, Bei­jing-based CRO Bio­cy­to­gen an­nounced that it has for­mal­ized and ex­pand­ed its April agree­ment with Mer­ck KGaA fol­low­ing an eval­u­a­tion pe­ri­od.

Un­der the part­ner­ship, Ger­man Mer­ck gets full ac­cess to an­ti­bod­ies dis­cov­ered by Bio­cy­to­gen’s pre­clin­i­cal mouse plat­form for an un­lim­it­ed num­ber of tar­gets. If the Ger­man phar­ma de­vel­ops, man­u­fac­tures, or even­tu­al­ly mar­kets any of the an­ti­bod­ies, Bio­cy­to­gen will col­lect down­stream mile­stone pay­ments.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER